Suggested remit: To appraise the clinical and cost effectiveness of ribociclib within its marketing authorisation for previously untreated advanced, hormone receptor-positive, HER2-negative breast cancer in premenopausal women.
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women. Following on from advice received from the company the timelines for this appraisal remain to be confirmed. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties as and when the situation changes.
 
Status Suspended
Process STA pre-2018
ID number 1307

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
18 July 2018 Suspended, As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women. Following on from advice received from the company the timelines for this appraisal remain to be confirmed. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties as and when the situation changes.
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
19 October 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance